Candida antigen in the treatment of basal cell carcinoma
Candida antigen in the treatment of basal cell carcinoma
复制标题
DOI：
10.1097/00042728-200501000-00003
复制
发表时间：
2005-01-01
影响因子：
2.4
通讯作者：
Cohen, J
中科院分区：
文献类型：
--
作者：
Aftergut, K;Curry, M;Cohen, J
背景。基底细胞癌（BCC）是最常见的皮肤癌。最近，人们对治疗基底细胞癌的各种免疫疗法重新产生了兴趣。目前的研究是病灶内念珠菌抗原治疗结节性 BCC 的随机、开放、安慰剂对照试验。 目的。本研究的目的是评估病灶内念珠菌抗原治疗基底细胞癌的安全性和有效性。结果。在对照组中，没有患者的肿瘤完全清除。在念珠菌组中，17 名患者中有 10 名 (56%) 的肿瘤完全清除。使用 Fisher 精确检验来比较两个治疗组。这表明清除率差异具有临界显着性，p 值为 0.105。结论。尽管重复注射念珠菌抗原的免疫疗法似乎可以有效清除浅表和结节性基底细胞癌，但它不太可能改变我们目前对基底细胞癌的治疗。
BACKGROUND. Basal cell carcinoma (BCC) is the most common skin cancer. Recently, there has been renewed interest in various immunotherapies in the treatment of BCC. The current study is a randomized, open-label, placebo-controlled trial of intralesional Candida antigen in the treatment of nodular BCC.OBJECTIVE. The objective of this study was to evaluate the safety and efficacy of intralesional Candida antigen in the treatment of BCC.RESULTS. In the control group, no patients had complete clearing of their tumor. In the Candida group, 10 of 17 (56%) patients had complete clearing of their tumor. The Fisher exact test was used to compare the two treatment groups. This showed the difference in clearance rates to be of borderline significance, with a p value of .105.CONCLUSION. Although immunotherapy with repeated injections of Candida antigen appears to be effective in clearing superficial and nodular BCCs, it is unlikely to alter our current treatment of BCC.